Technology
Health
Biotechnology

REGENXBIO

$62.45
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.86 (3.07%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell REGENXBIO and other stocks, options, ETFs, and crypto commission-free!

About

REGENXBIO Inc. Common Stock, also called REGENXBIO, is a biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Read More The company was founded by Kennth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Employees
192
Headquarters
Rockville, Maryland
Founded
2008
Market Cap
2.19B
Price-Earnings Ratio
21.64
Dividend Yield
0.00
Average Volume
569.38K
High Today
$62.88
Low Today
$60.12
Open Price
$60.51
Volume
196.45K
52 Week High
$85.10
52 Week Low
$26.80

Collections

Technology
Health
Biotechnology
Therapy
2015 IPO
US
North America

News

Simply Wall StMar 12

Is REGENXBIO Inc. (NASDAQ:RGNX) As Strong As Its Balance Sheet Indicates?

Mid-caps stocks, like REGENXBIO Inc. (NASDAQ:RGNX) with a market capitalization of US$2.1b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. While they are less talked about as an investment category, mid-cap risk-adjusted returns have generally been better than more commonly focused stocks that fall into the small- or large-cap categories. RGNX’s financial liquidity and debt position will be analysed in this article, to get an idea of w...

125
MarketBeatMar 10

Stock Price, News, & Analysis for Regenxbio

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase I/IIa clinical trials for the treatment ...

7
Yahoo FinanceMar 5

REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher

REGENXBIO Inc. RGNX was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company as the stock is now up 18.6% in the past one-month time frame. The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent...

91

Earnings

-$0.82
$0.47
$1.75
$3.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 7, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.